Pathophysiology of Huntington's disease: Time-dependent alterations in synaptic and receptor function

Neuroscience

Volumn 198, Issue , 2011, Pages 252-273

  Raymond, L A ^a   Andre V M ^b   Cepeda, C ^b   Gladding, C M ^a   Milnerwood, A J ^a   Levine, M S ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Direct and indirect pathways; Electrophysiology; Extrasynaptic NMDA receptors; Huntington's disease; Synaptic activity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUN2B PROTEIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

BRAIN CORTEX; CAG REPEAT; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC TRANSMISSION; EXCITATORY POSTSYNAPTIC POTENTIAL; EXCITOTOXICITY; GENE TARGETING; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; MEDIUM SIZED SPINY NEURON; MEMBRANE CONDUCTANCE; NERVE CELL; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS RETICULATA; SYNAPTIC TRANSMISSION; TRANSGENIC ANIMAL;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MICE; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES; TIME FACTORS;

EID: 81255149512     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.08.052     Document Type: Review

References (300)

1. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., Whetsell W.O., Penney J.B., Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992, 31:425-430.
2. Albin R.L., Reiner A., Anderson K.D., Penney J.B., Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 1990, 27:357-365.
3. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12:366-375.
4. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D.S., Tourtellotte W.W., Reiner A. Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990, 322:1293-1298.
5. André V.M., Cepeda C., Cummings D.M., Jocoy E.L., Fisher Y.E., William Yang X., Levine M.S. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci 2010, 31:14-28.
6. André V.M., Cepeda C., Fisher Y.E., Huynh M., Bardakjian N., Singh S., Yang X.W., Levine M.S. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci 2011, 31:1170-1182.
7. André V.M., Cepeda C., Levine M.S. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010, 16:163-178.
8. André V.M., Cepeda C., Venegas A., Gomez Y., Levine M.S. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J Neurophysiol 2006, 95:2108-2119.
9. André V.M., Fisher Y.E., Levine M.S. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front Syst Neurosci 2011, 5:46.
10. Andrews T.C., Weeks R.A., Turjanski N., Gunn R.N., Watkins L.H., Sahakian B., Hoddges J.R. Huntington's disease progression. PET and clinical observations. Brain 1999, 122(Pt 12):2353-2363.
11. Ariano M.A., Aronin N., Difiglia M., Tagle D.A., Sibley D.R., Leavitt B.R., Hayden M.R., Levine M.S. Striatal neurochemical changes in transgenic models of Huntington's disease. J Neurosci Res 2002, 68:716-729.
12. Ariano M.A., Cepeda C., Calvert C.R., Flores-Hernández J., Hernández-Echeagaray E., Klapstein G.J., Chandler S.H., Aronin N., DiFiglia M., Levine M.S. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol 2005, 93:2565-2574.
13. Arundine M., Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003, 34:325-337.
14. Bäckman L., Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. Scand J Psychol 2001, 42:287-296.
15. Backman L., Robins-Wahlin T.B., Lundin A., Ginovart N., Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997, 120(Pt 12):2207-2217.
16. Ballion B., Mallet N., Bézard E., Lanciego J.L., Ganon F. Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental Parkinsonism. Eur J Neurosci 2008, 27:2313-2321.
17. Barria A., Malinow R. Subunit-specific NMDA receptor trafficking to synapses. Neuron 2002, 35:345-353.
18. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993, 13:4181-4192.
19. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991, 11:1649-1659.
20. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
21. Beglinger L.J., O'Rourke J.J., Wang C., Langbehn D.R., Duff K., Paulsen J.S. Earliest functional declines in Huntington disease. Psychiatry Res 2010, 178:414-418.
22. Benn C.L., Slow E.J., Farrell L.A., Graham R., Deng Y., Hayden M.R., Cha J.H. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience 2007, 147:354-372.
23. Berretta S., Parthasarathy H.B., Graybiel A.M. Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J Neurosci 1997, 17:4752-4763.
24. Berrios G.E., Wagle A.C., Marková I.S., Wagle S.A., Ho L.W., Rubinsztein D.C., Whittaker J., Ffrench-Constant C., Kershaw A., Rosser A., Bak T., Hodges J.R. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. Psychiatry Res 2001, 102:217-225.
25. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 2000, 97:6809-6814.
26. Biolsi B., Cif L., Fertit H.E., Robles S.G., Coubes P. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg 2008, 109:130-132.
27. Bird E.D. Chemical pathology of Huntington's disease. Annu Rev Pharmacol Toxicol 1980, 20:533-551.
28. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
29. Boecker H., Ceballos-Baumann A., Bartenstein P., Weindl A., Siebner H.R., Fassbender T., Munz F., Schwaiger M., Conrad B. Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET. Brain 1999, 122(Pt 9):1651-1665.
30. Bogdanov M.B., Ferrante R.J., Kuemmerle S., Klivenyi P., Beal M.F. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J Neurochem 1998, 71:2642-2644.
31. Bohanna I., Georgiou-Karistianis N., Hannan A.J., Egan G.F. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008, 58:209-225.
32. Bolam J.P., Hanley J.J., Booth P.A., Bevan M.D. Synaptic organisation of the basal ganglia. J Anat 2000, 196(Pt 4):527-542.
33. Bolam J.P., Smith Y. The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat. Brain Res 1990, 529:57-78.
34. Braithwaite S.P., Paul S., Nairn A.C., Lombroso P.J. Synaptic plasticity: one STEP at a time. Trends Neurosci 2006, 29:452-458.
35. Brouillet E., Condé F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 1999, 59:427-468.
36. Brown T.B., Bogush A.I., Ehrlich M.E. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum Mol Genet 2008, 17:3095-3104.
37. Brusa L., Orlacchio A., Moschella V., Iani C., Bernardi G., Mercuri N.B. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009, 24:126-129.
38. Cao J., Semenova M.M., Solovyan V.T., Han J., Coffey E.T., Courtney M.J. Distinct requirements for p38alpha and c-Jun N-terminal kinase stress-activated protein kinases in different forms of apoptotic neuronal death. J Biol Chem 2004, 279:35903-35913.
39. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999, 19:3248-3257.
40. Cepeda C., André V.M., Yamazaki I., Wu N., Kleiman-Weiner M., Levine M.S. Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci 2008, 27:671-682.
41. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., Levine M.S. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 2001, 66:525-539.
42. Cepeda C., Cummings D.M., André V.M., Holley S.M., Levine M.S. Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro 2010, 2:e00033.
43. Cepeda C., Hurst R.S., Calvert C.R., Hernández-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003, 23:961-969.
44. Cepeda C., Itri J.N., Flores-Hernandez J., Hurst R.S., Calvert C.R., Levine M.S. Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. Eur J Neurosci 2001, 14:1577-1589.
45. Cepeda C., Starling A.J., Wu N., Nguyen O.K., Uzgil B., Soda T., André V.M., Ariano M.A., Levine M.S. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 2004, 78:855-867.
46. Cepeda C., Wu N., André V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog Neurobiol 2007, 81:253-271.
47. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A 1998, 95:6480-6485.
48. Chen B.S., Roche K.W. Regulation of NMDA receptors by phosphorylation. Neuropharmacology 2007, 53:362-368.
49. Chen N., Luo T., Wellington C., Metzler M., McCutcheon K., Hayden M.R., Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 1999, 72:1890-1898.
50. Cherry S.D. Calcium channel dysfunction in Huntington's disease 2009, The University of Tennessee Health Science Center, PhD Thesis, 128 pages.
51. Chevalier G., Deniau J.M. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 1990, 13:277-280.
52. Choi D.W., Maulucci-Gedde M., Kriegstein A.R. Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987, 7:357-368.
53. Christie J.M., Jane D.E., Monaghan D.T. Native N-methyl-d-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J Pharmacol Exp Ther 2000, 292:1169-1174.
54. Christopherson K.S., Sweeney N.T., Craven S.E., Kang R., El-Husseini Ael D., Bredt D.S. Lipid- and protein-mediated multimerization of PSD-95: implications for receptor clustering and assembly of synaptic protein networks. J Cell Sci 2003, 116:3213-3219.
55. Cicchetti F., Prensa L., Wu Y., Parent A. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Brain Res Rev 2000, 34:80-101.
56. Cowan C.M., Fan M.M., Fan J., Shehadeh J., Zhang L.Y., Graham R.K., Hayden M.R., Raymond L.A. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci 2008, 28:12725-12735.
57. Coyle J.T. An animal model for Huntington's disease. Biol Psychiatry 1979, 14:251-276.
58. Coyle J.T., Molliver M.E., Kuhar M.J. In situ injection of kainic acid: a new method for selectively lesioning neural cell bodies while sparing axons of passage. J Comp Neurol 1978, 180:301-323.
59. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262:689-695.
60. Coyle J.T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263:244-246.
61. Craven S.E., El-Husseini A.E., Bredt D.S. Synaptic targeting of the postsynaptic density protein PSD-95 mediated by lipid and protein motifs. Neuron 1999, 22:497-509.
62. Cull-Candy S.G., Leszkiewicz D.N. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 2004, 2004:re16.
63. Cummings D.M., André V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C., Levine M.S. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 2009, 29:10371-10386.
64. Cummings D.M., Cepeda C., Levine M.S. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro 2010, 2:e00036.
65. Cummings D.M., Milnerwood A.J., Dallérac G.M., Vatsavayai S.C., Hirst M.C., Murphy K.P.S.J. Abnormal cortical synaptic plasticity in mice transgenic for exon 1 of the human Huntington's disease mutation. Brain Res Bull 2007, 72:103-107.
66. Cummings D.M., Milnerwood A.J., Dallérac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., Murphy K.P. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 2006, 15:2856-2868.
67. Damiano M., Galvan L., Déglon N., Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2009, 1802:52-61.
68. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
69. Deng Y.P., Albin R.L., Penney J.B., Young A.B., Anderson K.D., Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 2004, 27:143-164.
70. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990, 13:286-289.
71. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
72. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev 1999, 51:7-61.
73. Ehlers M.D. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci 2003, 6:231-242.
74. El-Husseini A.E., Schnell E., Chetkovich D.M., Nicoll R.A., Bredt D.S. PSD-95 involvement in maturation of excitatory synapses. Science 2000, 290:1364-1368.
75. El-Husseini A.E., Topinka J.R., Lehrer-Graiwer J.E., Firestein B.L., Craven S.E., Aoki C., Bredt D.S. Ion channel clustering by membrane-associated guanylate kinases. Differential regulation by N-terminal lipid and metal binding motifs. J Biol Chem 2000, 275:23904-23910.
76. El-Husseini Ael D., Schnell E., Dakoji S., Sweeney N., Zhou Q., Prange O., Gauthier-Campbell C., Aguilera-Moreno A., Nicoll R.A., Bredt D.S. Synaptic strength regulated by palmitate cycling on PSD-95. Cell 2002, 108:849-863.
77. Faideau M., Kim J., Cormier K., Gilmore R., Welch M., Auregan G., Dufour N., Guillermier M., Brouillet E., Hantraye P., Déglon N., Ferrante R.J., Bonvento G. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 2010, 19:3053-3067.
78. Fan J., Cowan C.M., Zhang L.Y., Hayden M.R., Raymond L.A. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J Neurosci 2009, 29:10928-10938.
79. Fan J., Gladding C.M., Wang L., Zhang L.Y.J., Raymond L.A. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease 2011, Neuroscience Meeting Planner, Washington, D.C. Program: 14.07.
80. Fan M.M., Fernandes H.B., Zhang L.Y., Hayden M.R., Raymond L.A. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J Neurosci 2007, 27:3768-3779.
81. Fan M.M., Raymond L.A. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 2007, 81:272-293.
82. Fasano A., Mazzone P., Piano C., Quaranta D., Soleti F., Bentivoglio A.R. GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. Mov Disord 2008, 23:1289-1292.
83. Favaron M., Manev R.M., Rimland J.M., Candeo P., Beccaro M., Manev H. NMDA-stimulated expression of BDNF mRNA in cultured cerebellar granule neurones. Neuroreport 1993, 4:1171-1174.
84. Ferrante R.J., Beal M.F., Kowall N.W., Richardson E.P., Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987, 411:162-166.
85. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230:561-563.
86. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp Neurol 1993, 119:46-71.
87. Fonnum F., Storm-Mathisen J., Divac I. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 1981, 6:863-873.
88. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J Neurosci 2002, 22:4842-4849.
89. Gafni J., Hermel E., Young J.E., Wellington C.L., Hayden M.R., Ellerby L.M. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 2004, 279:20211-20220.
90. Garrett M.C., Soares-da-Silva P. Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 1992, 58:101-106.
91. Gencik M., Hammans C., Strehl H., Wagner N., Epplen J.T. Chorea Huntington: a rare case with childhood onset. Neuropediatrics 2002, 33:90-92.
92. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992, 15:133-139.
93. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 1992, 15:285-320.
94. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
95. Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987, 7:3915-3934.
96. Gertler T.S., Chan C.S., Surmeier D.J. Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci 2008, 28:10814-10824.
97. Ghasemzadeh M.B., Sharma S., Surmeier D.J., Eberwine J.H., Chesselet M.F. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study. Mol Pharmacol 1996, 49:852-859.
98. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997, 120(Pt 3):503-514.
99. Gittis A.H., Nelson A.B., Thwin M.T., Palop J.J., Kreitzer A.C. Distinct roles of GABAergic interneurons in the regulation of striatal output pathways. J Neurosci 2010, 30:2223-2234.
100. Gladding C.M., Milnerwood A.J., Zhang L.Y.J., Xu J., Lombroso P.J., Raymond L.A. Investigating the role of calpain and striatal-enriched tyrosine phosphatase (STEP) in mediating increased extrasynaptic NMDA receptor localization in a Huntington disease mouse model 2011, Neuroscience Meeting Planner, Washington, D.C. Program: 148.02.
101. Gladding CM, Raymond LA (in press) Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci., in press.
102. Goebel-Goody S.M., Davies K.D., Alvestad Linger R.M., Freund R.K., Browning M.D. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience 2009, 158:1446-1459.
103. Goto S., Hirano A., Rojas-Corona R.R. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol 1989, 25:298-304.
104. Graham R.K., Pouladi M.A., Joshi P., Lu G., Deng Y., Wu N.P., Figueroa B.E., Metzler M., André V.M., Slow E.J., Raymond L., Friedlander R., Levine M.S., Leavitt B.R., Hayden M.R. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 2009, 29:2193-2204.
105. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008, 28:6182-6195.
106. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990, 13:244-254.
107. Greene J.G., Porter R.H., Eller R.V., Greenamyre J.T. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 1993, 61:1151-1154.
108. Groc L., Heine M., Cousins S.L., Stephenson F.A., Lounis B., Cognet L., Choquet D. NMDA receptor surface mobility depends on NR2A-2B subunits. Proc Natl Acad Sci U S A 2006, 103:18769-18774.
109. Gu X., André V.M., Cepeda C., Li S.H., Li X.J., Levine M.S., Yang X.W. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener 2007, 2:8.
110. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., Iwasato T., Itohara S., Li X.J., Mody I., Heintz N., Yang X.W. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
111. Guidetti P., Luthi-Carter R.E., Augood S.J., Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 2004, 17:455-461.
112. Guttmann R.P., Baker D.L., Seifert K.M., Cohen A.S., Coulter D.A., Lynch D.R. Specific proteolysis of the NR2 subunit at multiple sites by calpain. J Neurochem 2001, 78:1083-1093.
113. Haber S.N., Nauta W.J. Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry. Neuroscience 1983, 9:245-260.
114. Hansen H.H., Briem T., Dzietko M., Sifringer M., Voss A., Rzeski W., Zdzisinska B., Thor F., Heumann R., Stepulak A., Bittigau P., Ikonomidou C. Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis 2004, 16:440-453.
115. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 2001, 14:1492-1504.
116. Hantraye P., Riche D., Maziere M., Isacson O. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 1990, 108:91-104.
117. Hardingham G.E., Arnold F.J., Bading H. A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication. Nat Neurosci 2001, 4:565-566.
118. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11:682-696.
119. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002, 5:405-414.
120. Harper P.S., Jones L. Huntington's disease: genetic and molecular studies. Huntington's disease 2002, 113-158. Oxford University Press, Oxford. G.P. Bates (Ed.).
121. Harris A.Z., Pettit D.L. Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J Physiol 2007, 584:509-519.
122. Harris A.Z., Pettit D.L. Recruiting extrasynaptic NMDA receptors augments synaptic signaling. J Neurophysiol 2008, 99:524-533.
123. Hayashi T., Thomas G.M., Huganir R.L. Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking. Neuron 2009, 64:213-226.
124. Hedreen J.C., Folstein S.E. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995, 54:105-120.
125. Heinsen H., Rüb U., Gangnus D., Jungkunz G., Bauer M., Ulmar G., Bethke B., Schüler M., Böcker F., Eisenmenger W., Götz M., Strik M. Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol 1996, 91:161-168.
126. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 2009, 29:3200-3205.
127. Heng M.Y., Tallaksen-Greene S.J., Detloff P.J., Albin R.L. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. J Neurosci 2007, 27:8989-8998.
128. Hernández-Espinosa D., Morton A.J. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. Brain Res Bull 2006, 69:669-679.
129. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., Chesselet M.F. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
130. Hickey M.A., Reynolds G.P., Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J Neurochem 2002, 81:46-59.
131. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
132. Huang K., Kang M.H., Askew C., Kang R., Sanders S.S., Wan J., Davis N.G., Hayden M.R. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2010, 40:207-215.
133. Huang K., Yanai A., Kang R., Arstikaitis P., Singaraja R.R., Metzler M., Mullard A., Haigh B., Gauthier-Campbell C., Gutekunst C.A., Hayden M.R., El-Husseini A. Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron 2004, 44:977-986.
134. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., Krishna G., Davies J.E., Ttofi E., Underwood B.R., Rubinsztein D.C. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008, 412:191-209.
135. Ivanov A., Pellegrino C., Rama S., Dumalska I., Salyha Y., Ben-Ari Y., Medina I. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol 2006, 572:789-798.
136. Jahanshahi A., Vlamings R., Kaya A.H., Lim L.W., Janssen M.L., Tan S., Visser-Vandewalle V., Steinbusch H.W., Temel Y. Hyperdopaminergic status in experimental Huntington disease. J Neuropathol Exp Neurol 2010, 69:910-917.
137. Jarabek B.R., Yasuda R.P., Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004, 127:505-516.
138. Jiang X., Tian F., Mearow K., Okagaki P., Lipsky R.H., Marini A.M. The excitoprotective effect of N-methyl-d-aspartate receptors is mediated by a brain-derived neurotrophic factor autocrine loop in cultured hippocampal neurons. J Neurochem 2005, 94:713-722.
139. Jocoy E.L., André V.M., Cummings D.M., Rao S.P., Wu N., Ramsey A.J., Caron M., Cepeda C., Levine M.S. Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatum. Front Syst Neurosci 2011, 5:28.
140. Johnson M.A., Rajan V., Miller C.E., Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J Neurochem 2006, 97:737-746.
141. Joshi P.R., Wu N.P., André V.M., Cummings D.M., Cepeda C., Joyce J.A., Carroll J.B., Leavitt B.R., Hayden M.R., Levine M.S., Bamford N.S. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 2009, 29:2414-2427.
142. Kaltenbach L.S., Romero E., Becklin R.R., Chettier R., Bell R., Phansalkar A., Strand A., Torcassi C., Savage J., Hurlburt A., Cha G.H., Ukani L., Chepanoske C.L., Zhen Y., Sahasrabudhe S., Olson J., Kurschner C., Ellerby L.M., Peltier J.M., Botas J., Hughes R.E. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007, 3:e82.
143. Kassubek J., Bernhard Landwehrmeyer G., Ecker D., Juengling F.D., Muche R., Schuller S., Weindl A., Peinemann A. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Neuroreport 2004, 15:363-365.
144. Kato A., Rouach N., Nicoll R.A., Bredt D.S. Activity-dependent NMDA receptor degradation mediated by retrotranslocation and ubiquitination. Proc Natl Acad Sci U S A 2005, 102:5600-5605.
145. Kawaguchi Y., Wilson C.J., Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 1990, 10:3421-3438.
146. Kemp J.M. The site of termination of afferent fibres on the neurones of the caudate nucleus. J Physiol 1970, 210:17P-18P.
147. Kew J.N., Richards J.G., Mutel V., Kemp J.A. Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons. J Neurosci 1998, 18:1935-1943.
148. Kim M.J., Dunah A.W., Wang Y.T., Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron 2005, 46:745-760.
149. Kim M.J., Jo D.G., Hong G.S., Kim B.J., Lai M., Cho D.H., Kim K.W., Bandyopadhyay A., Hong Y.M., Kim D.H., Cho C., Liu J.O., Snyder S.H., Jung Y.K. Calpain-dependent cleavage of cain/cabin1 activates calcineurin to mediate calcium-triggered cell death. Proc Natl Acad Sci U S A 2002, 99:9870-9875.
150. Kim S.H., Thomas C.A., André V.M., Cummings D.M., Cepeda C., Levine M.S., Ehrlich M.E. Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro 2011, 3(3). pii: e00060.
151. Kita H., Kitai S.T. Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res 1988, 447:346-352.
152. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 2001, 86:2667-2677.
153. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
154. Kremer H.P., Roos R.A., Dingjan G., Marani E., Bots G.T. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 1990, 49:371-382.
155. Kung V.W., Hassam R., Morton A.J., Jones S. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience 2007, 146:1571-1580.
156. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001, 21:9112-9123.
157. Landwehrmeyer G.B., Standaert D.G., Testa C.M., Penney J.B., Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 1995, 15:5297-5307.
158. Lavezzari G., McCallum J., Dewey C.M., Roche K.W. Subunit-specific regulation of NMDA receptor endocytosis. J Neurosci 2004, 24:6383-6391.
159. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121(Pt 7):1329-1341.
160. Lee S.T., Chu K., Park J.E., Kang L., Ko S.Y., Jung K.H., Kim M. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Brain Res 2006, 1118:199-207.
161. Lei W., Jiao Y., Del Mar N., Reiner A. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci 2004, 24:8289-8299.
162. Léveillé F., El Gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J 2008, 22:4258-4271.
163. Levine M.S., Cepeda C., Hickey M.A., Fleming S.M., Chesselet M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 2004, 27:691-697.
164. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knock-in mouse models of Huntington's disease. J Neurosci Res 1999, 58:515-532.
165. Li H., Wyman T., Yu Z.X., Li S.H., Li X.J. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 2003, 12:2021-2030.
166. Li J.Y., Plomann M., Brundin P. Huntington's disease: a synaptopathy?. Trends Mol Med 2003, 9:414-420.
167. Li L., Fan M., Icton C.D., Chen N., Leavitt B.R., Hayden M.R., Murphy T.H., Raymond L.A. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging 2003, 24:1113-1121.
168. Li L., Murphy T.H., Hayden M.R., Raymond L.A. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol 2004, 92:2738-2746.
169. Liévens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 2001, 8:807-821.
170. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001, 10:137-144.
171. Lin W.C., Chou Y.H. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. Am J Psychiatry 2008, 165:1207-1208.
172. Lin Y., Skeberdis V.A., Francesconi A., Bennett M.V., Zukin R.S. Postsynaptic density protein-95 regulates NMDA channel gating and surface expression. J Neurosci 2004, 24:10138-10148.
173. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 1999, 19:10428-10437.
174. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006, 5:160-170.
175. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994, 330:613-622.
176. Liu Y., Wong T.P., Aarts M., Rooyakkers A., Liu L., Lai T.W., Wu D.C., Lu J., Tymianski M., Craig A.M., Wang Y.T. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 2007, 27:2846-2857.
177. 2+ entry and a protein C kinase in rat cerebral cortex nerve terminals: an NMDA receptor-independent mechanism. Neurochem Int 2010, 57:168-176.
178. Lucas D.R., Newhouse J.P. The toxic effect of sodium l-glutamate on the inner layers of the retina. AMA 1957, 58:193-201.
179. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Standaert D.G., Thompson L.M., Cha J.H. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol Dis 2003, 14:624-636.
180. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000, 9:1259-1271.
181. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
182. Mayer M.L., Westbrook G.L. Permeation and block of N-methyl-d-aspartic acid receptor channels by divalent cations in mouse cultured central neurones. J Physiol 1987, 394:501-527.
183. McGeer E.G., McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976, 263:517-519.
184. McGeer P.L., McGeer E.G., Scherer U., Singh K. A glutamatergic corticostriatal path?. Brain Res 1977, 128:369-373.
185. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., Chesselet M.F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol 2000, 162:328-342.
186. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003, 465:11-26.
187. Menalled L.B., Sison J.D., Wu Y., Olivieri M., Li X.J., Li H., Zeitlin S., Chesselet M.F. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 2002, 22:8266-8276.
188. Milakovic T., Quintanilla R.A., Johnson G.V. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem 2006, 281:34785-34795.
189. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.
190. Miller B.R., Walker A.G., Shah A.S., Barton S.J., Rebec G.V. Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. J Neurophysiol 2008, 100:2205-2216.
191. Milnerwood A.J., Cummings D.M., Dallérac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum Mol Genet 2006, 15:1690-1703.
192. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W., Vasuta O.C., Graham R.K., Hayden M.R., Murphy T.H., Raymond L.A. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
193. Milnerwood A.J., Raymond L.A. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol 2007, 585:817-831.
194. Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci 2010, 33:513-523.
195. Mori H., Manabe T., Watanabe M., Satoh Y., Suzuki N., Toki S., Nakamura K., Yagi T., Kushiya E., Takahashi T., Inoue Y., Sakimura K., Mishina M. Role of the carboxy-terminal region of the GluR epsilon2 subunit in synaptic localization of the NMDA receptor channel. Neuron 1998, 21:571-580.
196. Morishima M., Kawaguchi Y. Recurrent connection patterns of corticostriatal pyramidal cells in frontal cortex. J Neurosci 2006, 26:4394-4405.
197. Moro E., Lang A.E., Strafella A.P., Poon Y.Y., Arango P.M., Dagher A., Hutchison W.D., Lozano A.M. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004, 56:290-294.
198. Morton A.J., Lagan M.A., Skepper J.N., Dunnett S.B. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J Neurocytol 2000, 29:679-702.
199. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 2000, 20:5115-5123.
200. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 2009, 15:1407-1413.
201. Oliveira J.M., Chen S., Almeida S., Riley R., Goncalves J., Oliveira C.R., Hayden M.R., Nicholls D.G., Ellerby L.M., Rego A.C. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci 2006, 26:11174-11186.
202. Oulis P., Mourikis I., Konstantakopoulos G., Papageorgiou S.G., Kouzoupis A.V. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease. J Neuropsychiatry Clin Neurosci 2010, 22. 352c.e4-352.e5.
203. Paladini C.A., Tepper J.M. GABAA and GABAB antagonists differentially affect the firing pattern of substantia nigra dopaminergic neurons in vivo. Synapse 1999, 32:165-176.
204. Panov A.V., Burke J.R., Strittmatter W.J., Greenamyre J.T. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys 2003, 410:1-6.
205. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002, 5:731-736.
206. Papadia S., Soriano F.X., Léveillé F., Martel M.A., Dakin K.A., Hansen H.H., Kaindl A., Sifringer M., Fowler J., Stefovska V., McKenzie G., Craigon M., Corriveau R., Ghazal P., Horsburgh K., Yankner B.A., Wyllie D.J., Ikonomidou C., Hardingham G.E. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 2008, 11:476-487.
207. Papadia S., Stevenson P., Hardingham N.R., Bading H., Hardingham G.E. Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci 2005, 25:4279-4287.
208. Parthasarathy H.B., Graybiel A.M. Cortically driven immediate-early gene expression reflects modular influence of sensorimotor cortex on identified striatal neurons in the squirrel monkey. J Neurosci 1997, 17:2477-2491.
209. Patel S., Rademacher D.J., Hillard C.J. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 2003, 306:880-888.
210. Paulsen J.S. Functional imaging in Huntington's disease. Exp Neurol 2009, 216:272-277.
211. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008, 79:874-880.
212. Pavese N., Gerhard A., Tai Y.F., Ho A.K., Turkheimer F., Barker R.A., Brooks D.J., Piccini P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66:1638-1643.
213. Pelkey K.A., Askalan R., Paul S., Kalia L.V., Nguyen T.H., Pitcher G.M., Salter M.W., Lombroso P.J. Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron 2002, 34:127-138.
214. Petersén A., Chase K., Puschban Z., DiFiglia M., Brundin P., Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp Neurol 2002, 175:297-300.
215. Petersén A., Gil J., Maat-Schieman M.L., Björkqvist M., Tanila H., Araújo I.M., Smith R., Popovic N., Wierup N., Norlén P., Li J.Y., Roos R.A., Sundler F., Mulder H., Brundin P. Orexin loss in Huntington's disease. Hum Mol Genet 2005, 14:39-47.
216. Petralia R.S., Wang Y.X., Hua F., Yi Z., Zhou A., Ge L., Stephenson F.A., Wenthold R.J. Organization of NMDA receptors at extrasynaptic locations. Neuroscience 2010, 167:68-87.
217. Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., Pisani A., Bernardi G., Ammassari-Teule M., Calabresi P. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 2006, 22:143-152.
218. Pisani A., Bernardi G., Ding J., Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 2007, 30:545-553.
219. Pouladi M.A., Graham R.K., Karasinska J.M., Xie Y., Santos R.D., Petersén A., Hayden M.R. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2009, 132:919-932.
220. Prybylowski K., Chang K., Sans N., Kan L., Vicini S., Wenthold R.J. The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 2005, 47:845-857.
221. Rao S.P., André V.M., Cepeda C., Levine M.S. Altered inhibitory inputs onto striatal medium-sized spiny neurons in the R6/2 mouse model of Huntington's disease 2010, Neuroscience Meeting Planner, San Diego, CA, Program: 861.16.
222. Rasmussen A., Macias R., Yescas P., Ochoa A., Davila G., Alonso E. Huntington disease in children: genotype-phenotype correlation. Neuropediatrics 2000, 31:190-194.
223. Rebec G.V., Conroy S.K., Barton S.J. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 2006, 137:327-336.
224. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 1988, 85:5733-5737.
225. Reiner A., Jiao Y., Del Mar N., Laverghetta A.V., Lei W.L. Differential morphology of pyramidal tract-type and intratelencephalically projecting-type corticostriatal neurons and their intrastriatal terminals in rats. J Comp Neurol 2003, 457:420-440.
226. Richfield E.K., Maguire-Zeiss K.A., Vonkeman H.E., Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol 1995, 38:852-861.
227. Rigby M., Le Bourdellès B., Heavens R.P., Kelly S., Smith D., Butler A., Hammans R., Hills R., Xuereb J.H., Hill R.G., Whiting P.J., Sirinathsinghji D.J. The messenger RNAs for the N-methyl-d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience 1996, 73:429-447.
228. Roche K.W., Standley S., McCallum J., Dune Ly C., Ehlers M.D., Wenthold R.J. Molecular determinants of NMDA receptor internalization. Nat Neurosci 2001, 4:794-802.
229. Rosas H.D., Feigin A.S., Hersch S.M. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx 2004, 1:263-272.
230. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
231. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
232. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Hevelone N., Hersch S.M. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?. Ann N Y Acad Sci 2008, 1147:196-205.
233. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
234. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., Salat D.H. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 2006, 21:1317-1325.
235. Salter M.W., Dong Y., Kalia L.V., Liu X.J., Pitcher G. Regulation of NMDA receptors by kinases and phosphatases. Biology of the NMDA receptor, Chapter 7 2009, CRC Press, Boca Raton, FL. A.M. VanDongen (Ed.).
236. Sanberg P.R., Calderon S.F., Giordano M., Tew J.M., Norman A.B. The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp Neurol 1989, 105:45-53.
237. Sanz-Clemente A., Matta J.A., Isaac J.T., Roche K.W. Casein kinase 2 regulates the NR2 subunit composition of synaptic NMDA receptors. Neuron 2010, 67:984-996.
238. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A.B., Vonsattel J.P., DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 1995, 64:397-404.
239. Schwarcz R., Coyle J.T. Striatal lesions with kainic acid: neurochemical characteristics. Brain Res 1977, 127:235-249.
240. Schwarcz R., Foster A.C., French E.D., Whetsell W.O., Köhler C. Excitotoxic models for neurodegenerative disorders. Life Sci 1984, 35:19-32.
241. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
242. Shehadeh J., Fernandes H.B., Zeron Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis 2006, 21:392-403.
243. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D.R., Myers R.M. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 1999, 8:763-774.
244. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005, 171:1001-1012.
245. Shuen J.A., Chen M., Gloss B., Calakos N. Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci 2008, 28:2681-2685.
246. Simpkins K.L., Guttmann R.P., Dong Y., Chen Z., Sokol S., Neumar R.W., Lynch D.R. Selective activation induced cleavage of the NR2B subunit by calpain. J Neurosci 2003, 23:11322-11331.
247. Singaraja R.R., Hadano S., Metzler M., Givan S., Wellington C.L., Warby S., Yanai A., Gutekunst C.A., Leavitt B.R., Yi H., Fichter K., Gan L., McCutcheon K., Chopra V., Michel J., Hersch S.M., Ikeda J.E., Hayden M.R. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet 2002, 11:2815-2828.
248. Singaraja RR, Huang K, Sanders SS, Milnerwood A, Hines R, Lerch J, Franciosi S, Drisdel R, Vaid K, Young FB, Doty C, Wan J, Bissada N, Henkelman RM, Green WN, Davis NG, Raymond LA, Hayden MR (in press) Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Hum Mol Genet.
249. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12:1555-1567.
250. Smith Y., Raju D.V., Pare J.F., Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 2004, 27:520-527.
251. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8:1051-1058.
252. Soriano F.X., Martel M.A., Papadia S., Vaslin A., Baxter P., Rickman C., Forder J., Tymianski M., Duncan R., Aarts M., Clarke P., Wyllie D.J., Hardingham G.E. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci 2008, 28:10696-10710.
253. Spampanato J., Gu X., Yang X.W., Mody I. Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 2008, 157:606-620.
254. Spokes E.G.S. The neurochemistry of Huntington's chorea. TINS 1981, 4:115-118.
255. Stack E.C., Dedeoglu A., Smith K.M., Cormier K., Kubilus J.K., Bogdanov M., Matson W.R., Yang L., Jenkins B.G., Luthi-Carter R., Kowall N.W., Hersch S.M., Beal M.F., Ferrante R.J. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 2007, 27:12908-12915.
256. Standaert D.G., Friberg I.K., Landwehrmeyer G.B., Young A.B., Penney J.B. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res Mol Brain Res 1999, 64:11-23.
257. Starling A.J., André V.M., Cepeda C., de Lima M., Chandler S.H., Levine M.S. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res 2005, 82:377-386.
258. Starr P.A., Kang G.A., Heath S., Shimamoto S., Turner R.S. Pallidal neuronal discharge in Huntington's disease: support for selective loss of striatal cells originating the indirect pathway. Exp Neurol 2008, 211:227-233.
259. Steiner H., Gerfen C.R. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience 1999, 88:795-810.
260. Stern E.A. Functional changes in neocortical activity in Huntington's disease model mice: an in vivo intracellular study. Front Syst Neurosci 2011, 5:47.
261. Strong T.V., Tagle D.A., Valdes J.M., Elmer L.W., Boehm K., Swaroop M., Kaatz K.W., Collins F.S., Albin R.L. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 1993, 5:259-265.
262. Surmeier D.J., Song W.J., Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 1996, 16:6579-6591.
263. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., Piccini P. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007, 72:148-151.
264. Tang T.S., Slow E., Lupu V., Stavrovskaya I.G., Sugimori M., Llinás R., Kristal B.S., Hayden M.R., Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 2005, 102:2602-2607.
265. Tang T.S., Tu H., Chan E.Y., Maximov A., Wang Z., Wellington C.L., Hayden M.R., Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
266. Tepper J.M., Koós T., Wilson C.J. GABAergic microcircuits in the neostriatum. Trends Neurosci 2004, 27:662-669.
267. Tepper J.M., Wilson C.J., Koós T. Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res Rev 2008, 58:272-281.
268. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
269. Thomas C.G., Miller A.J., Westbrook G.L. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol 2006, 95:1727-1734.
270. Thomas E.A., Coppola G., Tang B., Kuhn A., Kim S., Geschwind D.H., Brown T.B., Luthi-Carter R., Ehrlich M.E. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet 2011, 20:1049-1060.
271. Thu D.C., Oorschot D.E., Tippett L.J., Nana A.L., Hogg V.M., Synek B.J., Luthi-Carter R., Waldvogel H.J., Faull R.L. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010, 133:1094-1110.
272. Tobin A.J., Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol 2000, 10:531-536.
273. Tovar K.R., Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 1999, 19:4180-4188.
274. Tu W., Xu X., Peng L., Zhong X., Zhang W., Soundarapandian M.M., Balel C., Wang M., Jia N., Zhang W., Lew F., Chan S.L., Chen Y., Lu Y. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 2010, 140:222-234.
275. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2000, 97:8093-8097.
276. Uhl G.R., Navia B., Douglas J. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents. J Neurosci 1988, 8:4755-4764.
277. Van Oostrom J.C., Dekker M., Willemsen A.T., de Jong B.M., Roos R.A., Leenders K.L. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur J Neurol 2009, 16:226-231.
278. Van Raamsdonk J.M., Murphy Z., Slow E.J., Leavitt B.R., Hayden M.R. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet 2005, 14:3823-3835.
279. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 2005, 25:4169-4180.
280. Vincent S., Hokfelt T., Christensson I., Terenius L. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur J Pharmacol 1982, 85:251-252.
281. von Hörsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., Bader M., Pabst R., Kobbe P., Krotova J., Stiller D., Kask A., Vaarmann A., Rathke-Hartlieb S., Schulz J.B., Grasshoff U., Bauer I., Vieira-Saecker A.M., Paul M., Jones L., Lindenberg K.S., Landwehrmeyer B., Bauer A., Li X.J., Riess O. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003, 12:617-624.
282. Vonsattel J.P., DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998, 57:369-384.
283. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985, 44:559-577.
284. Wahl A.S., Buchthal B., Rode F., Bomholt S.F., Freitag H.E., Hardingham G.E., Rønn L.C., Bading H. Hypoxic/ischemic conditions induce expression of the putative pro-death gene Clca1 via activation of extrasynaptic N-methyl-d-aspartate receptors. Neuroscience 2009, 158:344-352.
285. Walker A.G., Miller B.R., Fritsch J.N., Barton S.J., Rebec G.V. Altered information processing in the prefrontal cortex of Huntington's disease mouse models. J Neurosci 2008, 28:8973-8982.
286. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000, 9:503-513.
287. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 1997, 17:404-410.
288. Wilson C.J., Chang H.T., Kitai S.T. Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum. J Neurosci 1990, 10:508-519.
289. Wood J.D., MacMillan J.C., Harper P.S., Lowenstein P.R., Jones A.L. Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. Hum Mol Genet 1996, 5:481-487.
290. Wu H.Y., Hsu F.C., Gleichman A.J., Baconguis I., Coulter D.A., Lynch D.R. Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems. J Biol Chem 2007, 282:20075-20087.
291. Xia P., Chen H.S., Zhang D., Lipton S.A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 2010, 30:11246-11250.
292. Xifró X., Giralt A., Saavedra A., García-Martínez J.M., Díaz-Hernández M., Lucas J.J., Alberch J., Pérez-Navarro E. Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. Neurobiol Dis 2009, 36:461-469.
293. Xu J., Kurup P., Zhang Y., Goebel-Goody S.M., Wu P.H., Hawasli A.H., Baum M.L., Bibb J.A., Lombroso P.J. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci 2009, 29:9330-9343.
294. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
295. Young A.B., Greenamyre J.T., Hollingsworth Z., Albin R., D'Amato C., Shoulson I., Penney J.B. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988, 241:981-983.
296. Zeron M.M., Fernandes H.B., Krebs C., Shehadeh J., Wellington C.L., Leavitt B.R., Baimbridge K.G., Hayden M.R., Raymond L.A. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol Cell Neurosci 2004, 25:469-479.
297. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
298. Zhang H., Li Q., Graham R.K., Slow E., Hayden M.R., Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis 2008, 31:80-88.
299. Zhang S.J., Zou M., Lu L., Lau D., Ditzel D.A., Delucinge-Vivier C., Aso Y., Descombes P., Bading H. Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet 2009, 5:e1000604.
300. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007, 81:294-330.